Is Dhampur Bio overvalued or undervalued?

As of 7 October 2025, the valuation grade for Dhampur Bio has moved from very attractive to attractive. The company is currently assessed as undervalued, particularly given its low Price to Book Value of 0.54 and EV to Sales ratio of 0.87. The PE Ratio stands at a striking -96.30, indicating significant losses, while the EV to EBITDA ratio is 16.17, which is relatively high compared to peers. In comparison to its industry peers, EID Parry is deemed very expensive with a PE of 23.8, and Balrampur Chini is rated fair with a PE of 23.21 and an EV to EBITDA of 18.34. Despite the current undervaluation, Dhampur Bio has underperformed against the Sensex, with a year-to-date return of -28.2% compared to the Sensex's 4.85%. This performance may reflect the company's challenges, but the valuation metrics suggest potential upside for investors.